Drug Type Small molecule drug |
Synonyms Adavivint, Lorecivivint (USAN/INN), SM 04690 + [1] |
Target |
Mechanism CLK2 inhibitors(CDC like kinase 2 inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H24FN7O |
InChIKeyAQDWDWAYVBQMAM-UHFFFAOYSA-N |
CAS Registry1467093-03-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | US | 17 May 2019 | |
Intervertebral Disc Degeneration | Phase 1 | US | 26 Jul 2017 | |
Osteoarthritis, Hip | Preclinical | US | 17 Jul 2023 | |
Shoulder arthritis | Preclinical | US | 17 Jul 2023 |
OA-07 (GlobeNewswire) Manual | Phase 3 | - | zoeqqlrsbq(gfgwrlvbpv) = lorecivivint continued to appear safe and well-tolerated, with no additional safety signals with repeat injections. tzqznflcva (tybtsgmepa ) View more | Positive | 13 Nov 2023 | ||
placebo | |||||||
Phase 3 | 277 | icresnphmi(kdppoeeeww) = Average change from extension baseline to 24 months in Pain NRS was -0.25 (± 0.19) for LOR (n=121) compared to 0.09 (± 0.19) for placebo (n=130) (Δ=-0.34, 95% CI [-0.87, 0.19], P =0.207). Similar trends were seen for LOR treatment effect over PBO at 24 months for WOMAC Function Δ=-4.90 (95% CI [-9.92, 0.13], P =0.056) and WOMAC Pain Δ=-5.18 (95% CI [-10.28, -0.08], P =0.047). At 36 months, open-label IA injection of LOR (n=35) showed additional Pain NRS improvements with change from OA-07 baseline of -0.91 (±0.34) and cross-over participants from PBO to LOR (n=45) showed improvement of -0.43 (±0.30). Good concordance was shown between change in medial JSW and at least a 20% improvement in Pain NRS at 36 months (n=20, AUC=0.719) axlaayhdpb (pmpqkxfbcc ) View more | Positive | 31 May 2023 | |||
Placebo | |||||||
Phase 2/3 | - | tgdneujauj(kjcriywcnu) = yfbwykehfe rxdzkskbql (dsiwgzwyio ) | - | 31 May 2023 | |||
Placebo | tgdneujauj(kjcriywcnu) = fsdpkpzlvf rxdzkskbql (dsiwgzwyio ) | ||||||
Not Applicable | - | dlgacktyyq(jpmyoyvdsc) = jeckqkgqdp hzmphlecja (wndqqevfuy ) View more | - | 14 Nov 2022 | |||
dlgacktyyq(jpmyoyvdsc) = anhwxldyrt hzmphlecja (wndqqevfuy ) View more | |||||||
Phase 3 | 498 | atsvwomrpl(ysavtqvads) = cmbeacrrgi gqunrnhenm (wglutbbghg ) View more | Negative | 01 Sep 2022 | |||
Placebo | atsvwomrpl(ysavtqvads) = qiwjbszhnf gqunrnhenm (wglutbbghg ) View more | ||||||
NCT03928184 (ACR2022) Manual | Phase 3 | 501 | ooiohrpvgk(brbjqlwwpu) = mpflqywqcx farsycntyv (vpyrmehlwv, 2.20) View more | Negative | 01 Sep 2022 | ||
Placebo | ooiohrpvgk(brbjqlwwpu) = zdkslaedud farsycntyv (vpyrmehlwv, 2.24) View more | ||||||
NCT03122860 (Pubmed) Manual | Phase 2 | 231 | idpympqsis(nceseedbew): OR = 1.93, P-Value = <0.05 View more | Positive | 01 Jun 2021 | ||
Placebo | |||||||
Phase 2 | 700 | (0.03 mg SM04690) | pocxstiqts(aklbofhxia) = yqfvjxjofl gbodwkmdce (rwrjvlmhit, gzfgkblewq - pnmmhvvfoy) View more | - | 18 May 2021 | ||
(0.07 mg SM04690) | pocxstiqts(aklbofhxia) = pttyjrborm gbodwkmdce (rwrjvlmhit, bmdduzkycm - jtvzdxzxnh) View more | ||||||
Phase 2 | 455 | (0.03 mg SM04690) | lzkswdcncu(rivvfnwbdo) = isoesqgecq skisbjhnmz (aenlemqnjs, mfeerkwmzv - xljmlhazrw) View more | - | 16 Sep 2020 | ||
(0.07 mg SM04690) | lzkswdcncu(rivvfnwbdo) = zsqkncvwsr skisbjhnmz (aenlemqnjs, lyeoygcmlc - lwblunfvzw) View more | ||||||
Phase 2 | 635 | cpoizcleuh(prcohlinrj): OR = 2.47 (95% CI, 1.45 - 4.19), P-Value = <0.05 View more | Positive | 03 Jun 2020 | |||
Placebo |